News

Novo Nordisk Adds Ozempic to Direct-to-Consumer Offerings, at $499 Per Month. Why GoodRx Stock Spikes.

GoodRx offers coupons for reduced prescription drug prices at retail pharmacies. The company says patients will be able to ...
StockStory.org on MSN3h

Why GoodRx (GDRX) Stock Is Trading Up Today

Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company announced a ...

Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of ...
PharmExec2h

Novo Nordisk Announces Lower Cost of Ozempic to $499-Per-Month for Self-Paying Patients

Novo Nordisk reduces Ozempic's price to $499/month for self-paying patients, enhancing access to essential diabetes treatment ...

Novo Nordisk slashes price of Ozempic in half to $499 for cash-paying, eligible U.S. patients

Who benefits? The reduced price applies to self-paying patients—those without insurance, or whose insurance doesn’t cover ...
Fierce Pharma7h

Novo Nordisk unveils $499 cash-pay Ozempic offering amid continued compounder competition

Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for ...

GoodRx stock soars after striking deal to sell Novo Nordisk's GLP-1s for $499/month

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.

Is Novo Nordisk deal the much-needed catalyst for Goodrx stock?

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...

Stock Movers: Novo Nordisk, GoodRX, CVS

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...